Tower Research Capital (TRC)’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.04K | Buy |
+794
| New | +$9.3K | ﹤0.01% | 4025 |
|
|
2025
Q3 | – | Sell |
-185
| Closed | -$2.06K | – | 5456 |
|
|
2025
Q2 | $2.06K | Buy |
+185
| New | +$1.63K | ﹤0.01% | 4708 |
|
|
2025
Q1 | – | Sell |
-466
| Closed | -$7.75K | – | 5552 |
|
|
2024
Q4 | $7.75K | Buy |
+466
| New | +$7.57K | ﹤0.01% | 4042 |
|
|
2024
Q3 | – | Sell |
-1,248
| Closed | -$18.1K | – | 5883 |
|
|
2024
Q2 | $18.1K | Buy |
1,248
+150
| +14% | +$2.5K | ﹤0.01% | 3807 |
|
|
2024
Q1 | $17K | Sell |
1,098
-807
| -42% | -$17.4K | ﹤0.01% | 3144 |
|
|
2023
Q4 | $53.3K | Buy |
1,905
+1,657
| +668% | +$43.5K | ﹤0.01% | 3096 |
|
|
2023
Q3 | $11.8K | Buy |
248
+47
| +23% | +$3.59K | ﹤0.01% | 3956 |
|
|
2023
Q2 | $19.2K | Sell |
201
-25
| -11% | -$2.72K | ﹤0.01% | 3421 |
|
|
2023
Q1 | $26K | Sell |
226
-472
| -68% | -$51.1K | ﹤0.01% | 3157 |
|
|
2022
Q4 | $78K | Buy |
698
+303
| +77% | +$40.6K | ﹤0.01% | 2024 |
|
|
2022
Q3 | $50K | Buy |
395
+26
| +7% | +$2.66K | ﹤0.01% | 3154 |
|
|
2022
Q2 | $25K | Sell |
369
-483
| -57% | -$41.6K | ﹤0.01% | 3563 |
|
|
2022
Q1 | $121K | Sell |
852
-735
| -46% | -$113K | ﹤0.01% | 2070 |
|
|
2021
Q4 | $264K | Sell |
1,587
-172
| -10% | -$27.3K | ﹤0.01% | 1558 |
|
|
2021
Q3 | $245K | Buy |
1,759
+1,270
| +260% | +$248K | 0.01% | 1618 |
|
|
2021
Q2 | $234K | Sell |
489
-2,673
| -85% | -$1.13M | 0.01% | 1800 |
|
|
2021
Q1 | $1.3M | Buy |
3,162
+3,048
| +2,674% | +$1.4M | 0.02% | 642 |
|
|
2020
Q4 | $56K | Sell |
114
-539
| -83% | -$316K | ﹤0.01% | 2998 |
|
|
2020
Q3 | $370K | Buy |
653
+168
| +35% | +$55.9K | ﹤0.01% | 1999 |
|
|
2020
Q2 | $46K | Buy |
+485
| New | +$42.6K | ﹤0.01% | 3115 |
|
|
2020
Q1 | – | Sell |
-616
| Closed | -$42K | – | 3544 |
|
|
2019
Q4 | $42K | Buy |
+616
| New | +$45.7K | ﹤0.01% | 1445 |
|
|
2019
Q3 | – | Sell |
-434
| Closed | -$28K | – | 4349 |
|
|
2019
Q2 | $28K | Buy |
434
+422
| +3,517% | +$40.1K | ﹤0.01% | 1947 |
|
|
2019
Q1 | $2K | Sell |
12
-726
| -98% | -$88.5K | ﹤0.01% | 3426 |
|
|
2018
Q4 | $67K | Buy |
738
+454
| +160% | +$63.5K | ﹤0.01% | 1147 |
|
|
2018
Q3 | $43K | Buy |
284
+236
| +492% | +$38.2K | ﹤0.01% | 1850 |
|
|
2018
Q2 | $8K | Sell |
48
-311
| -87% | -$50.8K | ﹤0.01% | 2883 |
|
|
2018
Q1 | $53K | Buy |
359
+253
| +239% | +$48.5K | ﹤0.01% | 1646 |
|
|
2017
Q4 | $21K | Sell |
106
-176
| -62% | -$36.2K | ﹤0.01% | 2029 |
|
|
2017
Q3 | $90K | Buy |
282
+68
| +32% | +$18.6K | 0.01% | 1462 |
|
|
2017
Q2 | $48K | Buy |
214
+209
| +4,180% | +$42.9K | 0.01% | 770 |
|
|
2017
Q1 | $1K | Sell |
5
-114
| -96% | -$23.1K | ﹤0.01% | 2811 |
|
|
2016
Q4 | $24K | Sell |
119
-17
| -13% | -$3.71K | ﹤0.01% | 1978 |
|
|
2016
Q3 | $34K | Buy |
+136
| New | +$47.7K | ﹤0.01% | 1342 |
|
|
2016
Q2 | – | Sell |
-49
| Closed | -$26K | – | 4743 |
|
|
2016
Q1 | $26K | Buy |
49
+44
| +880% | +$23K | ﹤0.01% | 1157 |
|
|
2015
Q4 | $4K | Buy |
5
+1
| +25% | +$657 | ﹤0.01% | 3215 |
|
|
2015
Q3 | $3K | Buy |
+4
| New | +$3.26K | ﹤0.01% | 3143 |
|
Other funds holding MCRB
FP
VCM
VFT
Tower Research Capital (TRC)'s MCRB Position: Q1 2026 in Review
Tower Research Capital (TRC) opened a new position in Seres Therapeutics (MCRB) in Q1 2026: 794 shares worth $7.04K. The stake represents ﹤0.01% of the portfolio and ranks #4025 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in MCRB as recently as Q2 2025.
Tower Research Capital (TRC) first reported a position in MCRB in Q3 2015 and has held it in 36 quarters since. The position peaked at $1.3M in Q1 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.
- Tower Research Capital (TRC) held 794 shares of Seres Therapeutics worth $7.04K as of Q1 2026.
- Seres Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
- Seres Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4025 holding.
- Tower Research Capital (TRC) first reported a position in Seres Therapeutics in Q3 2015 and has held it in 36 quarters since.
- Tower Research Capital (TRC)'s Seres Therapeutics position peaked at $1.3M in Q1 2021.
- 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.